Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 7/20 | 0.57 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | UQCRB | P14927 | 1/20 | 0.50 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16325550 | 0.88 | FFAR4 (0.63) | HSD17B2KIF11KDM1AFFAR4FFAR1 | |
| SCHEMBL13852837 | 0.88 | HSD17B2 (0.68) | HSD17B2CYP2C9FFAR4UQCRBCA1 | |
| SCHEMBL13852835 | 0.86 | HSD17B2 (0.57) | HSD17B2PTGES2FFAR4FFAR1CA1 | |
| SCHEMBL13852833 | 0.85 | HSD17B2 (0.63) | HSD17B2FFAR4 | |
| SCHEMBL7589492 | 0.84 | PTGES2 (0.56) | HSD17B2PTGES2KDM1ACYP2D6CYP2C9 | |
| SCHEMBL15248886 | 0.84 | HSD17B2 (0.74) | HSD17B2FFAR4UQCRBPSDCA1 | |
| SCHEMBL13629343 | 0.83 | NPC1 (0.52) | PTGES2KIF11KDM1ACYP2D6CYP2C9 | |
| SCHEMBL13615106 | 0.83 | FFAR4 (0.72) | HSD17B2CYP2C9FFAR4 | |
| SCHEMBL14403258 | 0.82 | PTGES2 (0.65) | HSD17B2PTGES2CYP2C9HSD11B1UQCRB | |
| SCHEMBL16187974 | 0.81 | HSD17B2 (0.67) | HSD17B2UQCRBPSDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | HSD17B2 4198/4885PTGES2 547/4885KIF11 1465/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | HSD17B2 4325/4885PTGES2 841/4885KIF11 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.